We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Opdivo-Yervoy

News List

Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial nasdaq
November 28, 2018
Bristol-Myers Squibb Company BMYannounced that the phase III CheckMate-451 study on immuno-oncology drug Opdivo in combination with Yervoy was unsuccessful....
Bristol-Myers reports positive results for Opdivo-Yervoy combination for advanced melanoma pharmaceutical-technology
October 23, 2018
Bristol-Myers Squibb has announced positive results from its trial into the efficacy of combination therapy with Opdivo (nivolumab) and Yervoy (ipilimumab), compared with either drug as a monotherapy, for patients with advanced melanoma.
Korea approves Opdivo-Yervoy for renal cell carcinoma treatment biospectrumasia
September 29, 2018
The approval is based on a clinical trial called CheckMate-214.
Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37% fiercepharma
September 11, 2017
MADRID, Spain—Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo,